MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
MannKind Corporation (Nasdaq: MNKD) will present at the Lytham Partners Investor Select Conference on January 31, 2023, at 9:00 am ET. CEO Michael Castagna and CFO Steven B. Binder will participate in this virtual event, which aims to discuss the company’s innovations in inhaled therapeutic products for endocrine and orphan lung diseases. The presentation will be accessible on the company's website and archived for later viewing. Attendees can also engage in one-on-one meetings with management by contacting Lytham Partners.
MannKind focuses on meeting serious medical needs in diabetes and pulmonary diseases through advanced delivery systems.
- None.
- None.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Steven B. Binder, will participate in the Lytham Partners Investor Select Conference taking place virtually on Tuesday, January 31, 2023.
The Company’s webcast presentation will be available for viewing at 9:00am ET on Tuesday, January 31, 2023, on the Company's website at Events & Presentations or https://investors.mannkindcorp.com/events-and-presentations. The webcast will also be archived and available for replay.
Management will be participating in virtual one-on-one meetings. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram.
MannKind Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
FAQ
What date will MannKind Corporation present at the Lytham Partners Investor Select Conference?
Who will represent MannKind Corporation at the conference?
What time is MannKind's presentation during the Lytham Partners Investor Select Conference?
Where can I watch MannKind Corporation's conference presentation?
Is there an opportunity to meet with MannKind management during the conference?
